The Community Guide

- gsearch

Search Results

Narrow Results:

2022 1
2021 1
2016 1

Germany 1

Journal Article 3

Letter 1

1 - 3 of 3 Results

Refine Results

Refine Results:

Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, February–March 2021

CITE Title : Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, February–March 2021 Personal Author(s) : Tober-Lau, Pinkus;Schwarz, Tatjana;Hillus, David;Spieckermann, Jana;Helbig, Elisa T.;Lippert, Lena J.;Thibeault, Charlotte;Koch, Willi;Bergfeld, Leon;Niemeyer, Daniela;Mühlemann, Barbara;Conrad, Claudia;Kasper, Stefanie;Münn, Friederike;Kunitz, Frank;Jones, Terry C.;Suttorp, Norbert;Drosten, Christian;Sander, Leif Erik;Kurth, Florian;Corman, Victor M.; Published Date : August 2021 Source : Emerg Infect Dis. 27(8):2169-2173 URL : https://stacks.cdc.gov/view/cdc/108809 Tober-Lau, Pinkus et al. (2021). Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, February–March 2021. 27(8). Tober-Lau, Pinkus et al. "Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, February–March 2021" 27, no. 8 (2021) Tober-Lau, Pinkus et al. "Outbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, February–March 2021" vol. 27, no. 8, 2021 Export RIS Citation Information.

:

Tober-Lau, Pinkus ;

Schwarz, Tatjana

August 2021 | Emerg Infect Dis. 27(8):2169-2173

:

One week after second vaccinations were administered, an outbreak of B.1.1.7 lineage severe acute respiratory syndrome coronavirus 2 infections occurr...
Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections

CITE Title : Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections Personal Author(s) : Tober-Lau, Pinkus;Gruell, Henning;Vanshylla, Kanika;Koch, Willi M.;Hillus, David;Schommers, Philipp;Suárez, Isabelle;Suttorp, Norbert;Sander, Leif Erik;Klein, Florian;Kurth, Florian; Published Date : 5 2022 Source : Emerg Infect Dis. 2022; 28(5):1050-1052 URL : https://stacks.cdc.gov/view/cdc/117307 Tober-Lau, Pinkus et al. (2022). Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections. 28(5). Tober-Lau, Pinkus et al. "Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections" 28, no. 5 (2022) Tober-Lau, Pinkus et al. "Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections" vol. 28, no. 5, 2022 Export RIS Citation Information.

:

Tober-Lau, Pinkus ;

Gruell, Henning

5 2022 | Emerg Infect Dis. 2022; 28(5):1050-1052

:

To determine neutralizing activity against the severe acute respiratory syndrome coronavirus 2 ancestral strain and 4 variants of concern, we tested s...
Hemolysis after Oral Artemisinin Combination Therapy for Uncomplicated Plasmodium falciparum Malaria

CITE Title : Hemolysis after Oral Artemisinin Combination Therapy for Uncomplicated Plasmodium falciparum Malaria Personal Author(s) : Kurth, Florian;Lingscheid, Tilman;Steiner, Florian;Stegemann, Miriam S.;Bélard, Sabine;Menner, Nikolai;Pongratz, Peter;Kim, Johanna;von Bernuth, Horst;Mayer, Beate;Damm, Georg;Seehofer, Daniel;Salama, Abdulgabar;Suttorp, Norbert;Zoller, Thomas; Published Date : Aug 2016 Source : Emerg Infect Dis. 22(8):1381-1386. URL : https://stacks.cdc.gov/view/cdc/40852 Kurth, Florian et al. (2016). Hemolysis after Oral Artemisinin Combination Therapy for Uncomplicated Plasmodium falciparum Malaria. 22(8). Kurth, Florian et al. "Hemolysis after Oral Artemisinin Combination Therapy for Uncomplicated Plasmodium falciparum Malaria" 22, no. 8 (2016) Kurth, Florian et al. "Hemolysis after Oral Artemisinin Combination Therapy for Uncomplicated Plasmodium falciparum Malaria" vol. 22, no. 8, 2016 Export RIS Citation Information.

:

Kurth, Florian ;

Lingscheid, Tilman

Aug 2016 | Emerg Infect Dis. 22(8):1381-1386.

:

Episodes of delayed hemolysis 2-6 weeks after treatment of severe malaria with intravenous artesunate have been described. We performed a prospective ...